M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2024; Provides Earnings Guidance for the Year Ending March 31, 2025
April 26, 2024 at 07:00 am
Share
M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2024. For the six months, the company expects net sales of JPY 127,000 million, operating profit of JPY 28,000 million, net profit of JPY 19,500 million, Net profit attributable to owners of parent of JPY 17,500 million or JPY 25.77 basic earnings per share.
For the year ending March 31, 2025, the company expects net sales of JPY 268,000 million to JPY 273,000 million, operating profit of JPY 67,000 million to JPY 70,000 million, net profit of JPY 47,000 million to JPY 49,000 million, Net profit attributable to owners of parent of JPY 44,000 million to JPY 46,000 million. Basic earnings per share of JPY 64.80 to JPY 67.75.
M3, Inc. specializes in the provision of online services dedicated to the health field. Net sales (before intra-group eliminations) break down by activity as follows:
- medical marketing support services (40.3%): services enabling doctors and health professionals to search for medical resources, use the latest medical news, exchange opinions, learn about medical products and services and career development, etc. via m3.com., MR-kun, MDLinx and MEDI: GATE;
- support services to medical institutions (16.5%):
- clinical trial related services (10.7%): clinical trial support and clinical trial operations management services;
- human resources services (6.6%);
- other (1.6%): including marketing assistance and surveys of affiliated medical companies via specialized sites.
The balance of sales (24.3%) concerns international activities.
M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2024; Provides Earnings Guidance for the Year Ending March 31, 2025
M3, INC. 
